Access Clinical Trials Cultivation 
NORML
APRIL 8, 2020
The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.
Americans for Safe Access
JUNE 2, 2020
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada.
NORML
OCTOBER 21, 2019
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.
NORML
MARCH 1, 2019
… Without access to an expanded range of cannabis products engineered under FDA-approved Good Manufacturing Practices, scientific research cannot hope to keep pace with the ever expanding recreational and medicinal cannabis marketplace.” ” The APA represents nearly 120,000 researchers and clinicians. .”
NORML
JANUARY 18, 2019
House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.
Cannabis Law Report
MARCH 30, 2022
Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects.
Expert insights. Personalized for you.
357 
Let's personalize your content